Helpline
+91 8892 555 000
Email : contactus@ordindia.in

Refocusing on Rare Diseases

The US Food and Drug Administration (FDA) approval in December 2023, of two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of a rare...

Read More

Rare disease of children: Kerala Family plans to move SC seeking assisted death

KOTTAYAM : Smitha Antony and Manu Joseph seem to have hit a brick wall in terms of their physical and emotional agony. The couple from Kozhuvanal, in Kottayam district, are...

Read More

Two-month-old receives life-saving bone marrow transplant

A two-month-old baby girl in Mumbai has become one of the youngest patients to receive a bone marrow transplant from an unrelated donor. The baby was diagnosed with a rare...

Read More

ORDI News letter Nov 2023

...

Read More

Clinical trial

...

Read More

Nerve Disorder : A1 tool can Aid in screening

...

Read More

Statement Regarding the Termination of Sanofi’s Proposed Acquisition of Maze Therapeutics’ Pompe Disease Drug

Following Sanofi’s decision to terminate its proposed acquisition of an exclusive license to Maze Therapeutics Inc.’s developmental drug to treat Pompe disease, the Federal Trade Commission moved to dismiss its...

Read More

ORDI Corporate Booklet

Click here to download the...

Read More

ORDI Press Statement

...

Read More

ORDI News letter Oct 2023

...

Read More

Highslide for Wordpress Plugin